Latest News & Insights
Stay Up to Date with Our Community
Featured
May 14, 2025
Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance of Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental...
Loading...
May 14, 2025
Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance...
April 28, 2025
Capsida will also present data from its potential best-in-class programs for...
April 3, 2025
GCase elevations meaningfully exceeding efficacy threshold, well-tolerated safety profile, and IV-administration...
March 25, 2025
Neuron23 today announced the publication of a manuscript in the Proceedings of...
March 24, 2025
Data from the Phase 1 healthy volunteer study of NEU-411 will...
March 17, 2025
Financing led by funds managed by Blue Owl Capital; Senior Managing...
March 3, 2025
LTG-001 demonstrated favorable safety and tolerability profile with predictable pharmacokinetics in...
January 7, 2025
Capsida to receive a $40 million license payment and is eligible...
December 19, 2024
Westlake BioPartners leads $30 million Series A extension, bringing the startup’s...